Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment.

Literature DB >> 24901568

Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment.

Michael Pollak¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Guanidines
Metformin

Year: 2014 PMID： 24901568 DOI： 10.1038/nm.3596

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

15 in total

1. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

Authors: M R Owen; E Doran; A P Halestrap
Journal: Biochem J Date: 2000-06-15 Impact factor: 3.857

Review 2. Potential applications for biguanides in oncology.

Authors: Michael Pollak
Journal: J Clin Invest Date: 2013-09-03 Impact factor: 14.808

3. Targeting oxidative phosphorylation: why, when, and how.

Authors: Michael Pollak
Journal: Cancer Cell Date: 2013-03-18 Impact factor: 31.743

4. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

Authors: Mahvash Zakikhani; Ryan Dowling; I George Fantus; Nahum Sonenberg; Michael Pollak
Journal: Cancer Res Date: 2006-10-23 Impact factor: 12.701

5. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

Authors: Marc Foretz; Sophie Hébrard; Jocelyne Leclerc; Elham Zarrinpashneh; Maud Soty; Gilles Mithieux; Kei Sakamoto; Fabrizio Andreelli; Benoit Viollet
Journal: J Clin Invest Date: 2010-06-23 Impact factor: 14.808

Review 6. The insulin and insulin-like growth factor receptor family in neoplasia: an update.

Authors: Michael Pollak
Journal: Nat Rev Cancer Date: 2012-02-16 Impact factor: 60.716

7. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.

Authors: C Algire; L Amrein; M Bazile; S David; M Zakikhani; M Pollak
Journal: Oncogene Date: 2010-11-22 Impact factor: 9.867

8. High and typical 18F-FDG bowel uptake in patients treated with metformin.

Authors: Eric Gontier; Emmanuelle Fourme; Myriam Wartski; Cyrille Blondet; Gerald Bonardel; Elise Le Stanc; Marina Mantzarides; Herve Foehrenbach; Alain-Paul Pecking; Jean-Louis Alberini
Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-05 Impact factor: 9.236

9. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides.

Authors: Kıvanç Birsoy; Richard Possemato; Franziska K Lorbeer; Erol C Bayraktar; Prathapan Thiru; Burcu Yucel; Tim Wang; Walter W Chen; Clary B Clish; David M Sabatini
Journal: Nature Date: 2014-03-16 Impact factor: 49.962

Review 10. Metformin and the risk of cancer: time-related biases in observational studies.

Authors: Samy Suissa; Laurent Azoulay
Journal: Diabetes Care Date: 2012-12 Impact factor: 19.112

43 in total

1. Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies.

Authors: Balaraman Kalyanaraman; Gang Cheng; Micael Hardy; Olivier Ouari; Adam Sikora; Jacek Zielonka; Michael B Dwinell
Journal: Cell Biochem Biophys Date: 2017-04-21 Impact factor: 2.194

Review 2. Mitochondrial Metabolism as a Target for Cancer Therapy.

Authors: Karthik Vasan; Marie Werner; Navdeep S Chandel
Journal: Cell Metab Date: 2020-07-14 Impact factor: 27.287

3. Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin.

Authors: Dan Y Gui; Lucas B Sullivan; Alba Luengo; Aaron M Hosios; Lauren N Bush; Nadege Gitego; Shawn M Davidson; Elizaveta Freinkman; Craig J Thomas; Matthew G Vander Heiden
Journal: Cell Metab Date: 2016-10-13 Impact factor: 27.287

4. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).

Authors: M Joerger; R H N van Schaik; M L Becker; S Hayoz; M Pollak; R Cathomas; R Winterhalder; S Gillessen; C Rothermundt
Journal: Prostate Cancer Prostatic Dis Date: 2015-03-10 Impact factor: 5.554

5. High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome.

Authors: Laura Paleari; Jürgen Burhenne; Johanna Weiss; Sebastian Foersch; Wilfried Roth; Andrea Parodi; Michael Gnant; Thomas Bachleitner-Hofmann; Dominique Scherer; Cornelia M Ulrich; Borut Stabuc; Matteo Puntoni; Gianni Coccia; Marilena Petrera; Walter-Emil Haefeli; Andrea DeCensi
Journal: Gastroenterology Date: 2018-03-08 Impact factor: 22.682

Review 6. Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy.

Authors: Gadi Shlomai; Brian Neel; Derek LeRoith; Emily Jane Gallagher
Journal: J Clin Oncol Date: 2016-11-07 Impact factor: 44.544

7. Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines.

Authors: Nifang Niu; Tongzheng Liu; Junmei Cairns; Reynold C Ly; Xianglin Tan; Min Deng; Brooke L Fridley; Krishna R Kalari; Ryan P Abo; Gregory Jenkins; Anthony Batzler; Erin E Carlson; Poulami Barman; Sebastian Moran; Holger Heyn; Manel Esteller; Liewei Wang
Journal: Hum Mol Genet Date: 2016-11-01 Impact factor: 6.150